Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 11/20 | 0.64 |
| ▸ | BCHE | P06276 | 2/20 | 0.59 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6782561 | 0.86 | GRIA4 (0.68) | GRIA4GRIA2GRIA1GRIA3RAB9A | |
| SCHEMBL6782446 | 0.85 | GRIA4 (0.66) | GRIA4GRIA2GRIA1GRIA3RAB9A | |
| SCHEMBL5877947 | 0.83 | GRIA4 (0.61) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL338391 | 0.81 | GRIA4 (0.81) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL3704221 | 0.81 | GRIA4 (0.81) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6554405 | 0.81 | GRIA4 (0.81) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6763720 | 0.80 | GRIA4 (0.57) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6565117 | 0.80 | GRIA4 (0.77) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6782507 | 0.79 | GRIA4 (0.57) | GRIA4GRIA2GRIA1GRIA3RAB9A | |
| SCHEMBL5878488 | 0.79 | GRIA4 (0.63) | GRIA4GRIA2GRIA1GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135487-B2 | such as N-2-(4-Bromophenyl)propyl methanesulfonamide; sulfonamidation of the amine; glutamate receptor potentiators | ELI LILLY AND COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | ARNOLD MACKLIN B | 2006-02-09 | — | — | US | disclosed |
| EP-1528055-A2 | Sulphonamide Derivatives | Eli Lilly & Company (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-0860428-B1 | Sulphonamide derivatives | LILLY CO ELI (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1100497-B1 | HETEROCYCLYL SULPHONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | KNOBELSDORF JAMES ALLEN (US) | 2004-03-18 | — | — | US | disclosed |
| US-6693137-B1 | GLUTAMATE RECEPTOR POTENTIATION | ELI LILLY AND COMPANY | 2004-02-17 | — | — | US | disclosed |
| US-6596716-B2 | 2-propane-sulphonamide derivatives | ELI LILLY AND COMPANY | 2003-07-22 | — | — | US | disclosed |
| EP-0994110-B1 | Sulphonamide derivatives | LILLY CO ELI (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6525099-B1 | Potentiating glutamate receptor function; psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6358982-B1 | FOR THERAPY OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-20020002158-A1 | Sulphonamide derivatives | ARNOLD MACKLIN B (US) | 2002-01-03 | — | — | US | disclosed |
| US-6303816-B1 | Sulphonamide derivatives | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| EP-0994110-A1 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-2000006537-A1 | N-SUBSTITUTED SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006148-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | GRIN2C, GLRA2, GLRA1 | GRIA4 19/4885BCHE 2721/4885GRIA2 18/4885 |
| US-20020002158-A1 | Sulphonamide derivatives | GRIN2C, GRM1, GRM3 | GRIA4 20/4885BCHE 1726/4885GRIA2 27/4885 |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | GRIN2A, GRIN2B, GABRE | GRIA4 14/4885BCHE 1998/4885GRIA2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.